Send to

Choose Destination
Clin Immunol. 2011 Aug;140(2):142-51. doi: 10.1016/j.clim.2010.11.009. Epub 2010 Dec 24.

Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Author information

Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, NY 10016, USA.


Natural killer T (NKT) cells are known to play a role against certain microbial infections, including malaria and HIV, two major global infectious diseases. Strategies that can harness and amplify the immunotherapeutic potential of NKT cells can serve as powerful tools in the fight against such diseases. 7DW8-5, a novel glycolipid, may be one such tool. The interaction of 7DW8-5 with CD1d molecules induces activation of NKT cells, thereby activating various immune-competent cells including dendritic cells (DCs) to provide a significant adjuvant effect for several vaccines. This review discusses the discovery and characterization of 7DW8-5 and the practical considerations of its preclinical and clinical development as a potential glycolipid adjuvant for candidate malaria and HIV vaccines.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center